{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-263158","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2023-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.505688+00:00","generated_at":"2026-06-09T11:26:01.378388+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aligos raises $92M in private placement of shares and warrants","bullets":["Gross proceeds of $92.15M from sale of 31.4M shares, 81.1M pre-funded warrants, and 56.2M common warrants.","Combined price per share + common warrant is $0.8193; per pre-funded warrant + common warrant is $0.8192.","Common warrants have exercise price $0.7568 and expire Oct 25, 2030; pre-funded warrants have $0.0001 exercise price.","Closing occurred Oct 25, 2023; executives and directors entered lock-up agreements."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-263158","json":"https://secwatch.observer/filing/0001193125-23-263158.json","markdown":"https://secwatch.observer/filing/0001193125-23-263158.md","text":"https://secwatch.observer/filing/0001193125-23-263158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000119312523263158/0001193125-23-263158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000119312523263158/d533607d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T11:26:01.378388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0028b47c0ba31113f8e768cf549f01455025d023","claim":"Aligos Therapeutics, Inc. entered into Securities Purchase Agreement with certain investors (the \"Purchasers\") valued at approximately $92,149,996 (effective 2023-10-23).","evidence_excerpt":"On October 23, 2023, Aligos Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312523263158/0001193125-23-263158-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors (the \"Purchasers\")"},{"label":"Value","value":"approximately $92,149,996"},{"label":"Effective","value":"2023-10-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}